Neurogen Biomarking
About Neurogen Biomarking
The startup operates a patient-facing platform that utilizes at-home blood-based biomarker analysis and digital cognitive testing to facilitate early detection of Mild Cognitive Impairment and Alzheimer's disease. By providing accessible neurologic care, the platform aims to improve patient outcomes through timely intervention.
<problem> Early detection of Alzheimer's disease is often delayed due to the invasive and costly nature of traditional diagnostic methods like PET scans, as well as limited access to neurological specialists. This delay hinders timely intervention and access to emerging treatments that are most effective in the early stages of the disease. </problem> <solution> Neurogen Biomarking offers an at-home testing service that combines a blood-based biomarker analysis for pTau217, a key indicator of Alzheimer's pathology, with an online cognitive assessment. The service includes a convenient at-home blood draw performed by a mobile phlebotomist and a comprehensive cognitive evaluation powered by Linus Health. Test results are reviewed by board-certified neurologists, who provide telehealth consultations to discuss findings and develop personalized care plans. This integrated approach aims to provide individuals with earlier insights into their cognitive health, enabling proactive lifestyle changes and access to appropriate medical interventions. </solution> <features> - At-home blood test for pTau217 biomarker, providing a measure of Alzheimer's pathology - Online cognitive assessment powered by Linus Health, evaluating various cognitive domains - Convenient at-home blood draw service performed by a mobile phlebotomist - Review of test results by board-certified neurologists - Telehealth consultations to discuss results and personalized care plans - Personalized Brain Action Plan with recommended lifestyle changes to mitigate cognitive decline - Secure customer portal for accessing test results and scheduling appointments </features> <target_audience> The primary target audience includes adults aged 55 and older experiencing memory issues or cognitive decline, individuals with a family history of Alzheimer's disease, and those seeking proactive monitoring of their cognitive health. </target_audience>
What does Neurogen Biomarking do?
The startup operates a patient-facing platform that utilizes at-home blood-based biomarker analysis and digital cognitive testing to facilitate early detection of Mild Cognitive Impairment and Alzheimer's disease. By providing accessible neurologic care, the platform aims to improve patient outcomes through timely intervention.
Where is Neurogen Biomarking located?
Neurogen Biomarking is based in Germany.
When was Neurogen Biomarking founded?
Neurogen Biomarking was founded in 2024.
How much funding has Neurogen Biomarking raised?
Neurogen Biomarking has raised 8900000.
- Location
- Germany
- Founded
- 2024
- Funding
- 8900000
- Employees
- 5 employees